North American Society For Pediatric Gastroenterology, Hepatology & Nutrition

North American Society For Pediatric Gastroenterology, Hepatology & Nutrition

Issue: January 2022
Source:

Gupta SK, et al. Poster 271. Presented at: North American Society for Pediatric Gastroenterology, Hepatology & Nutrition Annual Meeting; Dec. 12-18, 2021 (virtual meeting).

Disclosures: Gupta reports consulting for Abbott, Adare Pharmaceuticals/Ellodi Pharmaceuticals, Allakos, DBV Technologies, Gossamer Bio, Medscape, QOL Medical, Receptos/Celgene/Bristol Myers Squibb and UpToDate, and has received research support from Shire.
December 16, 2021
1 min read
Save

Budesonide improves histologic, symptom response in pediatric EoE

Issue: January 2022
Source:

Gupta SK, et al. Poster 271. Presented at: North American Society for Pediatric Gastroenterology, Hepatology & Nutrition Annual Meeting; Dec. 12-18, 2021 (virtual meeting).

Disclosures: Gupta reports consulting for Abbott, Adare Pharmaceuticals/Ellodi Pharmaceuticals, Allakos, DBV Technologies, Gossamer Bio, Medscape, QOL Medical, Receptos/Celgene/Bristol Myers Squibb and UpToDate, and has received research support from Shire.
You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Budesonide oral suspension improved histologic, endoscopic and symptom response compared with placebo among pediatric patients with eosinophilic esophagitis, according to a study.

“Budesonide oral suspension (BOS) is an immediate-release swallowed topical corticosteroid optimized as a viscous suspension for patients with EoE,” Sandeep K. Gupta, MD, of the section of gastroenterology, hepatology and nutrition at Indiana University School of Medicine, and colleagues wrote. “Previous studies have shown that BOS improves symptomatic, histologic and endoscopic outcomes in adolescents and adults with EoE.”

Symptom response among pediatric patients with eosinophilic esophagitis and dysphagia treated with: Budesonide oral suspension; 68.9% VS. Placebo; 58.1%

In a post hoc analysis, researchers evaluated the safety and efficacy of 2 mg BOS twice daily among 76 pediatric patients aged 11 to 17 years with EoE and dysphagia. For 12 weeks, patients received 2 mg BOS (n = 45) or placebo (n = 31); peak eosinophil counts, the Dysphagia Symptom Questionnaire (DSQ) and the EoE Endoscopy Reference Score (EREFS) assessed histologic, symptomatic and endoscopic outcomes.

According to study results, pediatric patients treated with BOS had greater histologic response (1 eosinophil per high-power field [eos/hpf]: 42.2% vs. 0%; 6 eos/hpf: 46.7% vs. 6.5% and < 15 eos/hpf: 53.3% vs. 9.7%), symptom response (30% reduction in DSQ score: 68.9% vs. 58.1%) and combined histologic and symptom response (6 eos/hpf and 30% reduction in DSQ score: 31.1% vs. 3.2%) compared with placebo-treated patients. Further, patients treated with BOS also achieved a greater reduction in mean EREFS from baseline (–4.1 vs. –2.1). Gupta reported no significant differences in adverse events for BOS vs. placebo.

“BOS 2 mg twice daily significantly improved histologic, endoscopic and combined outcomes, as measured using stringent endpoints, compared with placebo,” Gupta and colleagues concluded. “In addition, BOS 2 mg twice daily was well tolerated in this pediatric population with EoE.”